Emergent BioSolutions (EBS) EBT Margin (2011 - 2026)

Emergent BioSolutions' EBT Margin history runs 16 years deep, the most recent figure standing at 8.58% for Q1 2026.

• In Q1 2026, EBT Margin fell 3313.0% year-over-year to 8.58%; the TTM figure through Mar 2026 stood at 0.52% (up 871.0% YoY), while the FY2025 annual figure was 11.15%, up 2484.0% from the prior year.
• EBT Margin was 8.58% for Q1 2026 at Emergent BioSolutions, up from 34.1% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 48.47% in Q3 2024 to a low of 539.6% in Q2 2024.
• Historically, EBT Margin has averaged 49.64% across 5 years, with a median of 18.59% in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT Margin plunged 46555 bps in 2024, then jumped 52768 bps in 2025.
• A 5-year view of EBT Margin shows it stood at 18.59% in 2022, then slipped by 6 bps to 19.7% in 2023, then gained by 28 bps to 14.18% in 2024, then sank by 141 bps to 34.1% in 2025, then soared by 125 bps to 8.58% in 2026.
• The last three EBT Margin figures came in at 8.58% (Q1 2026), 34.1% (Q4 2025), and 24.92% (Q3 2025), per Business Quant data.